Dr. Chamie on durability of UGN-101 in low-grade UTUC
“The reason that [long-term follow up is] important is because if you look at the best of hands, the incidence of recurrence of upper tract urothelial carcinoma, even for low and intermediate risk, is still very high,” says Karim Chamie, MD.
In this video, Karim Chamie, MD, discusses the background of the study, “Long-term recurrence free survival following UGN-101 treatment for low-grade upper tract urothelial carcinoma,” presented at the 2021 American Urological Association Annual Meeting, and how it builds on previous studies. Chamie is an associate professor of urology and director of the Urologic Oncology Fellowship at the University of California, Los Angeles.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
